Toshihiro Miyamoto
Expertise in
15
conditions

Toshihiro Miyamoto

Kanazawa, JP 
Expertise in
15
conditions
Kanazawa, JP 

Overview

Toshihiro Miyamoto practices practicing medicine in Kanazawa, Japan.

Miyamoto is highly rated in 15 conditions, according to our data. Their clinical expertise encompasses Leukemia, Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Adult T-Cell Leukemia, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 299 peer reviewed articles and participating in 1 clinical trial.

Locations

Kanazawa, Japan
Other Locations
Japan
Narita, Japan
Kashiwa, 2778561, Japan
Fukuoka, Japan
Higashi, 8128582, Japan
Hamamatsu, Japan
Chiba, 2778561, Japan
Nishi, Japan
Tokyo, 1138656, Japan
Gifu-shi, 5061205, Japan
Hiroshima, 7348553, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Phase: Phase 3

299 Total Publications

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.
QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.
Journal: Future oncology (London, England)
Published: July 11, 2026

Frequently Asked Questions about Toshihiro Miyamoto

Is Toshihiro Miyamoto a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Toshihiro Miyamoto is classified as an Elite expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Toshihiro Miyamoto participate in research or clinical trials?

Yes. Toshihiro Miyamoto has published 299 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Toshihiro Miyamoto's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Miyamoto's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 42 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile